Surmodics Management

Management Kriterienprüfungen 2/4

Surmodics' CEO ist Gary Maharaj , ernannt in Dec 2010, hat eine Amtszeit von 13.67 Jahren. Die jährliche Gesamtvergütung beträgt $3.53M , bestehend aus 18.2% Gehalt und 81.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.35% der Aktien des Unternehmens, im Wert von $7.69M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.3 Jahre bzw. 13.6 Jahre.

Wichtige Informationen

Gary Maharaj

Geschäftsführender

US$3.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	18.2%
Amtszeit als Geschäftsführer	13.8yrs
Eigentum des Geschäftsführers	1.4%
Durchschnittliche Amtszeit des Managements	6.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	13.7yrs

Jüngste Management Updates

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03

Recent updates

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Jun 06

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Jun 26

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Jun 22

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

May 14

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Apr 17

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Jan 08

Surmodics gets additional $125M in credit facility

Oct 17

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Jul 27

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Jul 22

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 03

Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Feb 04

Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?

Dec 24

Estimating The Fair Value Of Surmodics, Inc. (NASDAQ:SRDX)

Aug 13

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Gary Maharaj im Vergleich zu den Einnahmen von Surmodics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$1m
Mar 31 2024	n/a	n/a	US$14m
Dec 31 2023	n/a	n/a	US$6m
Sep 30 2023	US$4m	US$640k	-US$2m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$36m
Dec 31 2022	n/a	n/a	-US$32m
Sep 30 2022	US$3m	US$620k	-US$27m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	n/a	n/a	US$2m
Sep 30 2021	US$3m	US$602k	US$4m
Jun 30 2021	n/a	n/a	US$2m
Mar 31 2021	n/a	n/a	US$7m
Dec 31 2020	n/a	n/a	US$701k
Sep 30 2020	US$3m	US$585k	US$1m
Jun 30 2020	n/a	n/a	US$8m
Mar 31 2020	n/a	n/a	US$7m
Dec 31 2019	n/a	n/a	US$6m
Sep 30 2019	US$2m	US$568k	US$8m
Jun 30 2019	n/a	n/a	US$2m
Mar 31 2019	n/a	n/a	-US$2m
Dec 31 2018	n/a	n/a	-US$2m
Sep 30 2018	US$2m	US$551k	-US$4m
Jun 30 2018	n/a	n/a	-US$2m
Mar 31 2018	n/a	n/a	US$1m
Dec 31 2017	n/a	n/a	US$70k
Sep 30 2017	US$2m	US$526k	US$4m

Vergütung im Vergleich zum Markt: GaryDie Gesamtvergütung ($USD3.53M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD2.41M).

Entschädigung vs. Einkommen: GaryDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Gary Maharaj (61 yo)

13.8yrs

Amtszeit

US$3,527,263

Vergütung

Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Gary Maharaj	CEO, President & Director	13.8yrs	US$3.53m	1.42% $ 7.8m
Timothy Arens	Senior VP of Finance & Information Technology and CFO	6.3yrs	US$1.30m	0.54% $ 3.0m
Gordon Weber	Senior VP of Legal	4.3yrs	US$1.10m	0.16% $ 861.8k
Charles Olson	Senior VP & President of Medical Device Coatings	19.9yrs	US$1.12m	0.38% $ 2.1m
Teryl L. Sides	Senior VP & President of Vascular Interventions	2.3yrs	US$1.49m	0.26% $ 1.4m
John Manders	Corporate Controller	6.3yrs	keine Daten	0.058% $ 320.2k
Joel Suiter	Director of Corporate Development	no data	keine Daten	keine Daten
Joseph Stich	Senior VP of Human Resources & President of In Vitro Diagnostics	4.4yrs	US$970.92k	0.45% $ 2.5m

6.3yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrenes Management: SRDXDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.3 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Gary Maharaj	CEO, President & Director	13.8yrs	US$3.53m	1.42% $ 7.8m
Ronald Kalich	Independent Director	10.6yrs	US$186.50k	0.26% $ 1.4m
David Dantzker	Independent Director	13.7yrs	US$185.00k	0.27% $ 1.5m
Susan Knight	Independent Non-Executive Chair of the Board	16.7yrs	US$229.00k	0.23% $ 1.2m
José Bedoya	Independent Director	22.7yrs	US$176.50k	0.20% $ 1.1m
Lisa Heine	Independent Director	7.4yrs	US$176.50k	0.088% $ 483.1k

13.7yrs

Durchschnittliche Betriebszugehörigkeit

69yo

Durchschnittliches Alter

Erfahrener Vorstand: SRDXDie Vorstandsmitglieder sind sehr erfahren ( 13.6 ).

Surmodics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Surmodics, Inc., Annual General Meeting, Feb 08, 2024

Insider exercised options and sold US$107k worth of stock

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Independent Director exercised options and sold US$64k worth of stock

Independent Director notifies of intention to sell stock

Insufficient new directors

Recent updates

Surmodics, Inc. Suspends Earnings Guidance for the Fiscal 2024

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Price target decreased by 10% to US$52.33

GTCR LLC entered into a definitive agreement to acquire Surmodics, Inc. (NasdaqGS:SRDX) for approximately $620 million.

Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 24%

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024

New major risk - Revenue and earnings growth

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

Second quarter 2024 earnings released: EPS: US$0.017 (vs US$0.55 loss in 2Q 2023)

Surmodics, Inc. to Report Q2, 2024 Results on May 01, 2024

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System

Surmodics, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Surmodics, Inc., Annual General Meeting, Feb 08, 2024

Insider exercised options and sold US$107k worth of stock

Surmodics, Inc. Announces 24-Month Data from the Swing Trial Presented At VEITHsymposium

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Surmodics, Inc. Announces Swing Trial 24-Month Data to Be Presented At Veith Symposium on November 15

Surmodics, Inc. Announces Launch of Preside Medical Device Coating Technology, Providing Lubricity and Durability to a Broader Range of Complex Device Applications

Surmodics, Inc. to Report Q4, 2023 Results on Nov 08, 2023

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Consensus revenue estimates increase by 12%

Price target increased by 8.7% to US$59.50

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. to Report Q3, 2023 Results on Aug 02, 2023

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Surmodics, Inc.(NasdaqGS:SRDX) dropped from Russell 2000 Growth-Defensive Index

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Consensus revenue estimates increase by 11%

Surmodics, Inc. Receives FDA Approval for the SurVeil Drug-Coated Balloon

Surmodics Receives FDA 510(k) Clearance for Pounce LP Thrombectomy System

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Consensus EPS estimates upgraded to US$2.14 loss

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Surmodics, Inc. to Report Q1, 2023 Results on Feb 06, 2023

Consensus EPS estimates fall by 20%

Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil Drug-Coated Balloon

Price target decreased to US$61.00

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Independent Director exercised options and sold US$64k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Surmodics, Inc. Announces 24-Month Data from Its Transcend Clinical Trial At the Vascular InterVentional Advances

Surmodics, Inc. to Report Q4, 2022 Results on Nov 09, 2022

Surmodics, Inc. Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022

Surmodics gets additional $125M in credit facility

Surmodics, Inc. Announces 6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surmodics, Inc. Updates Earnings Guidance for the Fiscal Year 2022

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Insider exercised options and sold US$254k worth of stock

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Surmodics, Inc. to Report Q3, 2022 Results on Jul 27, 2022

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

Price target increased to US$74.00